{"schema_version":"1.0","type":"article","title":"The Next Phase of AI Drug Development: Making Molecules Survive as Drugs","url":"https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.md","lang":"en","date":"2026-06-13","publish_at":"2026-06-13T15:20:00+08:00","updated_at":"2026-06-13","category":"商業分析系列","topic":"商業分析系列","tags":["AI Drug Development","AnHorn Medicines","AI+PROTAC","AIMCADD","NVIDIA","Clinical Asset Engine","Biotech"],"summary":"AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.","key_points":[],"facts":[],"sections":["1. AI Drug Development Is Asking a Harder Question: Can Molecules Survive?","2. Three Years in the NVIDIA Ecosystem: Less About Exposure, More About Positioning","3. The AI Deal Wave: Big Pharma Is Buying Drug-Making Capability, Not AI Tools","4. Capital Efficiency and Clinical Speed: Why AnHorn Is More Than an AI Drug Discovery Company","5. AnHorn’s AI+PROTAC Druggability Flywheel: AH-001 Is Not the Endpoint; It Is the First Proof of Engine","6. Global AI-Native Drug Progress: The Real Gap Opens When Assets Reach the Clinic Faster","7. What AnHorn Still Needs to Prove: The Ability to Make Drugs Survive","Conclusion: In the Next Phase of AI Drug Development, Who Can Make Molecules Survive?","Disclosure and Publication Note","Selected References"],"references":[],"images":[{"alt":"Figure 1 | The next phase of AI drug development: from molecular generation to drug survival, human translation, and clinical asset creation","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-01.png"},{"alt":"Figure 2 | Three consecutive years in the NVIDIA ecosystem: from platform visibility to AI-native clinical asset positioning","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-02.png"},{"alt":"Figure 3 | The AI drug-development deal wave: Big Pharma is buying platforms, data, and clinical asset generation capability","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-03.png"},{"alt":"Figure 4 | AnHorn’s capital efficiency and three-layer closed-loop engine: US$11M, two clinical assets, and US$5.5M per clinical asset","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-04.png"},{"alt":"Figure 5 | AnHorn’s AI+PROTAC druggability flywheel: from disease biology to human translation and multi-asset replication","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-05.png"},{"alt":"Figure 6 | Representative AI-native drug development progress: company, asset, modality, speed, clinical stage, and indication","url":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-06.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/cover-ai-drug-survival.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-13）。The Next Phase of AI Drug Development: Making Molecules Survive as Drugs。https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-13-dcard-261654701.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}